Sanofi (SNYNF) - OTCPK - Current
  • Mon, May 2, 7:57 AM
    | Mon, May 2, 7:57 AM | 1 Comment
  • Mon, Apr. 4, 7:26 AM
    • March monthly performance was: +4.15%
    • AUM of $13.6B
    • 52-week performance vs. the S&P 500 is: -23%
    • $0.13 in dividends were paid in March
    • Top 10 Holdings as of 2/29/2016: Anheuser-Busch Inbev SA (OTCPK:AHBIF): 6.14%, Siemens AG (OTCPK:SMAWF): 5.08%, Unilever NV DR (OTCPK:UNLNF): 5.02%, Telefonica SA (OTCPK:TEFOF): 4.62%, Daimler AG (OTCPK:DDAIF): 4.19%, Sanofi SA (OTCPK:SNYNF): 4.11%, Banco Santander SA (OTCPK:BCDRF): 3.8%, Banco Bilbao Vizcaya Argentaria SA (BBVA): 3.49%, SAP SE (OTCPK:SAPGF): 3.07%, Bayer AG (OTCPK:BAYZF): 2.91%
    | Mon, Apr. 4, 7:26 AM
  • Wed, Mar. 2, 6:30 AM
    • February monthly performance was: -3.94%
    • AUM of $14.7B
    • 52-week performance vs. the S&P 500 is: -17%
    • No dividends were paid in February
    • Top 10 Holdings as of 1/29/2016: Anheuser-Busch Inbev SA (OTCPK:AHBIF): 6.7%, Siemens AG (OTCPK:SMAWF): 5.11%, Unilever NV DR (OTCPK:UNLNF): 5.05%, Telefonica SA (OTCPK:TEFOF): 4.71%, Sanofi SA (OTCPK:SNYNF): 4.21%, Daimler AG (OTCPK:DDAIF): 4.17%, Banco Santander SA (OTCPK:BCDRF): 3.89%, Banco Bilbao Vizcaya Argentaria SA (BBVA): 3.43%, SAP SE (OTCPK:SAPGF): 3.15%, Bayer AG (OTCPK:BAYZF): 3.06%
    | Wed, Mar. 2, 6:30 AM
  • Tue, Feb. 2, 9:00 AM
    • January monthly performance was: -3.38%
    • AUM of $15.3B
    • 52-week performance vs. the S&P 500 is: -10%
    • No dividends were paid in January
    • Top 10 Holdings as of 12/31/2015: Anheuser-Busch Inbev SA (OTCPK:AHBIF): 6.15%, Siemens AG (OTCPK:SMAWF): 4.85%, Telefonica SA (OTCPK:TEFOF): 4.81%, Daimler AG (OTCPK:DDAIF): 4.71%, Unilever NV DR (OTCPK:UNLNF): 4.61%, Banco Santander SA (OTCPK:BCDRF): 4.3%, Sanofi SA (OTCPK:SNYNF): 4.15%, Banco Bilbao Vizcaya Argentaria SA (BBVA): 3.74%, Bayer AG (OTCPK:BAYZF): 3.24%, Bayerische Motoren Werke AG (OTCPK:BAMXF): 3.18%
    | Tue, Feb. 2, 9:00 AM | 3 Comments
  • Mon, Jan. 4, 9:03 AM
    • December monthly performance was: -7.06%
    • AUM of $16.8B
    • 52-week performance vs. the S&P 500 is: -3%
    • $4.00 in dividends were paid in December
    • Top 10 Holdings as of 11/30/2015: Anheuser-Busch Inbev SA (OTCPK:AHBIF): 6.29%, Siemens AG (OTCPK:SMAWF): 5.08%, Telefonica SA (OTCPK:TEFOF): 5.0%, Daimler AG (OTCPK:DDAIF): 4.75%, Unilever NV DR (OTCPK:UNLNF): 4.58%, Banco Santander SA (OTCPK:BCDRF): 4.38%, Sanofi SA (OTCPK:SNYNF): 4.08%, Banco Bilbao Vizcaya Argentaria SA (BBVA): 4.05%, Bayer AG (OTCPK:BAYZF): 3.34%, Bayerische Motoren Werke AG (OTCPK:BAMXF): 3.23%
    | Mon, Jan. 4, 9:03 AM
  • Dec. 1, 2015, 9:28 AM
    • November monthly performance was: +3.16%
    • AUM of $21.7B
    • 52-week performance vs. the S&P 500 is: +4%
    • No dividends were paid in November
    • Top 10 Holdings as of 10/30/2015: Anheuser-Busch Inbev SA (OTCPK:AHBIF): 5.8%, Telefonica SA (OTCPK:TEFOF): 5.32%, Siemens AG (OTCPK:SMAWF): 4.93%, Unilever NV DR (OTCPK:UNLNF): 4.72%, Sanofi (OTCPK:SNYNF): 4.61%, Daimler AG (OTCPK:DDAIF): 4.55%, Banco Santander SA (OTCPK:BCDRF): 4.41%, Banco Bilbao Vizcaya Argentaria SA (BBVA): 4.24%, Bayer AG (OTCPK:BAYZF): 3.33%, Bayerische Motoren Werke AG (OTCPK:BAMXF): 3.06%
    | Dec. 1, 2015, 9:28 AM
  • Feb. 16, 2015, 9:59 AM
    • Sanofi (NYSE:SNY) is set to announce this week that Olivier Brandicourt, head of Bayer's (OTCPK:BAYRY) healthcare business, will become its new chief executive, Reuters reports quoting Le Figaro newspaper.
    • Brandicourt's name has been circulating for months as one of a few people suitable as a replacement for Chris Viehbacher, who sacked by Sanofi's board in October.
    | Feb. 16, 2015, 9:59 AM | 2 Comments
  • Jan. 8, 2015, 8:08 AM
    • MannKind (NASDAQ:MNKD) earns a $50M milestone payment from partner Sanofi (NYSE:SNY) (OTCQB:SNYNF) for the achievement of Afrezza-related manufacturing milestones.
    • It is eligible to receive up to $725M in further development, regulatory and sales milestones as well as a portion of the profits on sales of Afrezza.
    | Jan. 8, 2015, 8:08 AM | 28 Comments
  • Dec. 12, 2014, 10:26 AM
    • The FDA approves Sanofi (SNY -0.4%) (OTCQB:SNYNF) division Sanofi Pasteur's supplemental BLA for its Fluzone Intradermal Quadrivalent influenza vaccine. The new product helps protect adult patients (ages 18 - 64) from four strains of influenza virus which is an improvement over the trivalent version that has been available for three years.
    | Dec. 12, 2014, 10:26 AM
  • Dec. 5, 2014, 8:12 AM
    • In a wrongful termination lawsuit, paralegal Diane Ponte claims that ex-employer Sanofi (NYSE:SNY) (OTCQB:SNYNF) paid $34M in kickbacks to boost diabetes drug sales. She says former CEO Chris Viehbacher was in on the scheme.
    • Unsurprisingly, Mr. Viehbacher and Sanofi dispute her allegations. In an e-mail statement he says, "The allegations contained in this wrongful termination lawsuit are entirely baseless and are categorically false." Sanofi echoes his sentiment by stating, "Diane Ponte is a disgruntled former employee who is opportunistically attacking our company. The employment law allegations are without merit and Sanofi will vigorously defend the suit. We take this matter very seriously and will protect our company and our reputation."
    • Conspicuous by its absence in the company's statement is a reference to the alleged kickbacks.
    • Ms. Ponte says Sanofi management retaliated against her after she reported the fraud to her superiors.
    | Dec. 5, 2014, 8:12 AM | 2 Comments
  • Dec. 2, 2014, 9:32 AM
    • The FDA, under priority review, approves the use of Sanofi's (NYSE:SNY) (OTCQB:SNYNF) Priftin (rifapentine) for the treatment of latent tuberculosis infection (LTBI) in patients at least two years old when used in combination with isoniazid.
    • Priftin is only available in the U.S. It was approved in 1998, in combination with one or more antituberculosis drugs, for the treatment of active pulmonary TB caused by Mycobacterium turberculosis.
    • The company is exploring regulatory approval in other markets.
    | Dec. 2, 2014, 9:32 AM
  • Dec. 1, 2014, 7:41 AM
    • Sanofi (NYSE:SNY) (OTCQB:SNYNF) and Pozen (NASDAQ:POZN) "mutually agree" to terminate their commercialization agreement for PA8140 and PA32540 effective November 29, 2014. All rights to the products will revert back to Pozen at that time.
    • No specific reason (s) are disclosed explaining the move although Pozen will host a webcast this morning at 8:30 am ET to discuss the issue.
    • Henceforward, the two products will be referred to as Yosprala 81/40 (enteric-coated aspirin 81 mg/immediate release omeprazole 40 mg) and Yosprala 325/40 (enteric-coated aspirin 325 mg/immediate release omeprazole 40 mg).
    • The PDUFA date is December 30, 2014 for the FDA's review of Pozen's NDA resubmission. The company received a Complete Response Letter (CRL) on April 28, 2014 related to deficiencies noted during an on-site inspection of an ingredient maker.
    • Pozen President & CEO Dr. John Plachetka says, Our goal at Pozen continues to be to maximize shareholder return. Management and the BOD are taking this opportunity to evaluate all strategic options for Yosprala and Pozen. With respect to how well Yosprala may perform in the marketplace, we believe that the clinical profile of the drug, as described in the current FDA-proposed package insert, will meet or exceed the assumptions we made when we started our development and evaluated the commercial potential for this product."
    • POZN shares are off 10% premarket on light volume.
    • Previously: Pozen soars on Sanofi deal
    • Previously: Pozen receives a Complete Response Letter
    • Previously: Pozen resubmits NDA
    • Previously: PDUFA date set for PA8140/PA32540
    | Dec. 1, 2014, 7:41 AM | 1 Comment
  • Nov. 21, 2014, 8:04 AM
    • The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopts a positive opinion supporting approval of Celgene's (NASDAQ:CELG) Otezla (apremilast) for two indications: 1. the treatment of adult patients with moderate-to-severe plaque psoriasis who failed to respond to, or who are contraindicated for or are intolerant to, other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light (PUVA); 2. alone or in combination with Disease Modifying Antirheumatic Drugs (DMARDs) for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy. A final decision from the European Commission usually takes about 60 days.
    • Apremilast is a PDE4 inhibitor specific for cyclic AMP (cAMP). PDE4 inhibition results in increased cAMP levels which is thought to indirectly modulate the production of inflammatory mediators.
    • The FDA approved Otezla in March.
    • Previously: FDA approves Otezla
    • Previously: Otezla label expansion cleared in the U.S.
    • Related tickers: (NYSE:PFE) (NYSE:SNY) (OTCQB:SNYNF) (NYSEMKT:PLX) (NASDAQ:SHPG)
    | Nov. 21, 2014, 8:04 AM
  • Nov. 21, 2014, 7:38 AM
    • The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopts a positive opinion supporting approval for Genzyme's (NYSE:SNY) (OTCQB:SNYNF) Cerdelga (eliglustat) capsules for the treatment of certain adults with Gaucher disease type 1. A final decision by the European Commission usually takes about 60 days.
    • The FDA approved Cerdelga in August. It was the first oral therapy approved as a first-line treatment for Gaucher.
    • Previously: FDA approves new drug for Gaucher's disease
    • Related tickers: (NYSE:PFE) (NYSEMKT:PLX) (NASDAQ:SHPG)
    | Nov. 21, 2014, 7:38 AM
  • Nov. 20, 2014, 8:16 AM
    • The FDA grants Breakthrough Therapy status to Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi's (NYSE:SNY) (OTCQB:SNYNF) dupilumab for the treatment of adults with moderate-to-severe atopic dermatitis who are not adequately controlled with topical prescription therapy and/or for whom these treatments are not appropriate. Dupilumab is currently in Phase 3 development.
    • The Breakthrough Therapy designation includes all of the Fast Track features as well as more intensive FDA guidance and discussion including access to more senior agency managers.
    | Nov. 20, 2014, 8:16 AM | 3 Comments
  • Nov. 19, 2014, 12:35 PM
    • During the scientific sessions at the American Heart Association meeting in Chicago, investigators presented results from six Phase 3 clinical trials of Regeneron Pharmaceuticals (REGN +1.2%) and Sanofi's (SNY -0.2%) (OTCQB:SNYNF) cholesterol-lowering product candidate, alirocumab, compared to placebo or statins.
    • The trials assessed alirocumab in patients with hypercholesterolemia who were at high cardiovascular risk, had an inherited form of high cholesterol known as heterozygous familial hypercholesterolemia (HeFH) and/or a history of intolerance to two or more statins. All six studies met their primary efficacy endpoint of change from baseline in LDL-C at week 24. Patients receiving alirocumab showed a mean reduction in LDL-C from baseline of 36 - 62%, depending on the study, compared to the comparator drugs' mean reduction of 0.5 - 23%.
    • Regulatory submissions will be made to the FDA and EMA by the end of next month.
    • Alirocumab is a PCSK9 inhibitor that will compete with Amgen's (AMGN +0.2%) evolocumab for supremacy in what is expected to be a $10B post-statin market. Amgen filed its BLA in August, but Regeneron and Sanofi bought an FDA voucher for $67.5M a few months ago that will cut the FDA's review time from 10 months to six, meaning that the projected approval time for both drugs will be about the same (June).
    • Amgen filed a patent infringement lawsuit against the two firms last month.
    • Previously: Amgen sues Sanofi and Regeneron
    • Previously: FDA OK with Amgen's BLA for cholesterol-lowering drug
    • Previously: Biotechs to use priority review voucher for cholesterol-lowering drug candidate
    | Nov. 19, 2014, 12:35 PM | 4 Comments
Company Description
Currently, there's no company description for SNYNF.
Sector: Healthcare
Industry: Drug Related Products
Country: France